Logo image of LMDX

LUMIRADX LTD (LMDX) Stock Fundamental Analysis

USA - NASDAQ:LMDX - KYG5709L1095 - Common Stock

0.016 USD
-0.02 (-53.49%)
Last: 1/8/2024, 8:17:43 PM
0.0136 USD
0 (-15%)
After Hours: 1/8/2024, 8:17:43 PM
Fundamental Rating

1

Taking everything into account, LMDX scores 1 out of 10 in our fundamental rating. LMDX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. LMDX has a bad profitability rating. Also its financial health evaluation is rather negative. LMDX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year LMDX has reported negative net income.
In the past year LMDX has reported a negative cash flow from operations.
LMDX had negative earnings in each of the past 5 years.
In the past 5 years LMDX always reported negative operating cash flow.
LMDX Yearly Net Income VS EBIT VS OCF VS FCFLMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -100M -200M -300M -400M

1.2 Ratios

The Return On Assets of LMDX (-99.18%) is worse than 82.91% of its industry peers.
Industry RankSector Rank
ROA -99.18%
ROE N/A
ROIC N/A
ROA(3y)-54.66%
ROA(5y)-52.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMDX Yearly ROA, ROE, ROICLMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 100 -100 200 300 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LMDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMDX Yearly Profit, Operating, Gross MarginsLMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 -200 -400

1

2. Health

2.1 Basic Checks

LMDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LMDX has less shares outstanding
Compared to 1 year ago, LMDX has a worse debt to assets ratio.
LMDX Yearly Shares OutstandingLMDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M
LMDX Yearly Total Debt VS Total AssetsLMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -6.66, we must say that LMDX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.66, LMDX is doing worse than 72.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.66
ROIC/WACCN/A
WACC4.03%
LMDX Yearly LT Debt VS Equity VS FCFLMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.97 indicates that LMDX should not have too much problems paying its short term obligations.
LMDX's Current ratio of 1.97 is on the low side compared to the rest of the industry. LMDX is outperformed by 74.37% of its industry peers.
LMDX has a Quick Ratio of 1.01. This is a normal value and indicates that LMDX is financially healthy and should not expect problems in meeting its short term obligations.
LMDX has a Quick ratio of 1.01. This is amonst the worse of the industry: LMDX underperforms 82.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.01
LMDX Yearly Current Assets VS Current LiabilitesLMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 100M 200M 300M 400M

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.80% over the past year.
LMDX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -68.26%.
Measured over the past years, LMDX shows a very strong growth in Revenue. The Revenue has been growing by 122.52% on average per year.
EPS 1Y (TTM)1.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.41%
Revenue 1Y (TTM)-68.26%
Revenue growth 3Y122.52%
Revenue growth 5YN/A
Sales Q2Q%-53.02%

3.2 Future

The Earnings Per Share is expected to grow by 22.53% on average over the next years. This is a very strong growth
LMDX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.56% yearly.
EPS Next Y70.33%
EPS Next 2Y33.38%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue Next Year-64.72%
Revenue Next 2Y-27.23%
Revenue Next 3Y-9.52%
Revenue Next 5Y-3.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LMDX Yearly Revenue VS EstimatesLMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M
LMDX Yearly EPS VS EstimatesLMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.5 -1 -1.5

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LMDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LMDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LMDX Price Earnings VS Forward Price EarningsLMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMDX Per share dataLMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as LMDX's earnings are expected to grow with 22.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.38%
EPS Next 3Y22.53%

0

5. Dividend

5.1 Amount

No dividends for LMDX!.
Industry RankSector Rank
Dividend Yield N/A

LUMIRADX LTD

NASDAQ:LMDX (1/8/2024, 8:17:43 PM)

After market: 0.0136 0 (-15%)

0.016

-0.02 (-53.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10 2023-11-10/amc
Earnings (Next)03-19 2024-03-19/amc
Inst Owners0.11%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.63M
Revenue(TTM)126.50M
Net Income(TTM)-338.00M
Analysts82.5
Price Target1.22 (7525%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.35%
Min EPS beat(2)-12.04%
Max EPS beat(2)5.34%
EPS beat(4)1
Avg EPS beat(4)-35.59%
Min EPS beat(4)-77.22%
Max EPS beat(4)5.34%
EPS beat(8)2
Avg EPS beat(8)-68.43%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.56%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)11.29%
Revenue beat(4)2
Avg Revenue beat(4)3.57%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)11.29%
Revenue beat(8)5
Avg Revenue beat(8)10.8%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.42%
EPS NY rev (1m)0%
EPS NY rev (3m)5.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0.77
BVpS-1.31
TBVpS-1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.66%
ROA(5y)-52.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.03%
Cap/Sales 8.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.01
Altman-Z -6.66
F-Score1
WACC4.03%
ROIC/WACCN/A
Cap/Depr(3y)359.47%
Cap/Depr(5y)273.18%
Cap/Sales(3y)27.1%
Cap/Sales(5y)32.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.41%
EPS Next Y70.33%
EPS Next 2Y33.38%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-68.26%
Revenue growth 3Y122.52%
Revenue growth 5YN/A
Sales Q2Q%-53.02%
Revenue Next Year-64.72%
Revenue Next 2Y-27.23%
Revenue Next 3Y-9.52%
Revenue Next 5Y-3.56%
EBIT growth 1Y-149.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.43%
EBIT Next 3Y23.29%
EBIT Next 5YN/A
FCF growth 1Y22.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.46%
OCF growth 3YN/A
OCF growth 5YN/A

LUMIRADX LTD / LMDX FAQ

Can you provide the ChartMill fundamental rating for LUMIRADX LTD?

ChartMill assigns a fundamental rating of 1 / 10 to LMDX.


What is the valuation status for LMDX stock?

ChartMill assigns a valuation rating of 1 / 10 to LUMIRADX LTD (LMDX). This can be considered as Overvalued.


How profitable is LUMIRADX LTD (LMDX) stock?

LUMIRADX LTD (LMDX) has a profitability rating of 0 / 10.